The United Kingdom and the United States have reached a important bilateral deal that will keep no duties on UK drug exports being sold in the American market.
Agreement Details of the Accord
As part of the deal, the UK has pledged to raise funding on medicines through the public health system. This commitment ensures that tariffs on these vital exports will stay at nothing for a period of 36 months.
This development is in response to earlier warnings to dramatically increase tariffs on branded drug products, with figures floated as high as double the cost.
"This arrangement with the United Kingdom reinforces the global environment for innovative medicines and brings long-overdue fairness to American-British pharmaceutical trade," a release noted.
Trade Significance
Pharmaceuticals are one of the Britain's largest exports to the US, which is easily the largest destination for major companies like GSK and AstraZeneca.
Trade data indicate that in the year leading up to September, the UK sold pharmaceutical products valued at over eleven billion pounds to the US. This value made up a significant portion of British export trade in that span.
"This guarantee safeguards work, stimulates investment and sets the stage for the UK to emerge as a international leader for life sciences," a minister commented.
Key British Pledges
The pact entails several notable changes from the United Kingdom:
- Revised Affordability Limit: The UK will lift the cost ceiling at which it deems new therapies to be prohibitively costly by 25%.
- Increased NHS Spending: There is a target to increase total NHS spending on treatments from 0.3 percent of the national economy to 0.6% over the coming ten years.
- Refund Ceiling: The percentage pharmaceutical firms must return to the NHS to control costs will be restricted at fifteen percent. Previously, refunds exceeded twenty percent.
Broader Context
The deal takes place against a ongoing dispute between the pharmaceutical industry and the UK government over spending levels and approval rates.
These tensions were intensified by claims that American consumers were charged several times more for the equivalent treatments than people in the UK and Europe.
Recently, several significant manufacturing plans in the UK have been delayed or scrapped, while substantial expansions have been directed toward American operations.
A senior figure publicly accepted that the NHS must spend more on medicines, noting that its spending on drugs had declined as a share of its overall budget over the last ten years.
